JAK2 and Splenomegaly: 72‐year‐old male, JAK2‐positive PMF with splenomegaly and constitutional symptomsRuxolitinib monotherapyWorsening splenomegaly, symptoms and leucocytosisRineterkib plus ruxolitinib via ADORE (NCT04097821)No change to disease statusRetinopathy requiring withdrawal from studyRuxolitinib and navitoclax via TRANSFORM‐2 (NCT04468984)Progressive leucocytosis and thrombocytopeniaRuxolitinib and hydroxycarbamideTransformation to blast phaseAzacitidine and venetoclaxPancytopenia, splenomegaly and infectious complicationsSupportive care and splenic radiotherapyDied